Day: December 9, 2020

Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases

PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University...

VitalHub Announces Addition of Award-Winning Synopsis iQ to Recently Expanded Multi-Year Licensing Deal with King’s College Hospital NHS Foundation Trust

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...

error: Content is protected !!